AparnaChandraSwaminathanMD

Pulmonology • Durham, NC

Critical Care Medicine

Physician

Join to view full profile

Dr. Swaminathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Swaminathan's full profile

Already have an account?

Office
2301 Erwin Rd
Durham, NC 27705
Phone+1 610-442-9029

Fax+1 919-620-4921

Education & Training

Duke University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 2015 - 2019
Duke University HospitalResidency, Internal Medicine, 2012 - 2015
Case Western Reserve University School of MedicineClass of 2012

Certifications & Licensure

NC State Medical License 2012 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Publications & Presentations

PubMed

Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.
Aparna C Swaminathan, Jeremy M Weber, Jamie L Todd, Scott M Palmer, Megan L Neely
Respiratory Research. 2025-02-28
Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.
Aparna C Swaminathan, Amber Meservey, Alice Parish, Cynthia L Green, Kishan Parikh
JHLT Open. 2024-11-01
Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease.
Aparna C Swaminathan, Molly McFatrich, Laura Mkumba, Lauren Wright, Carrie A Redlich
Respiratory Research. 2024-10-15

Grant Support

Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung DiseasesDUKE UNIVERSITY2023–2028
Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung DiseasesDUKE UNIVERSITY2023–2028
Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung DiseasesDUKE UNIVERSITY2023–2028